Pasar al contenido principal

ESTUDIO EN PROFUNDIDAD DE 3 VIAS DE SEÑALIZACION BIOLOGICAMENTE DISTINTAS QUE CONDUCEN A STEMNESS, CELL DESDIFERENCIACION Y RESISTENCIA A TERAPIA EN CANCER.

PID2021-122629OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

NAD pool as an antitumor target against cancer stem cells in head and neck cancer

  • Navas, Lola E.
  • Blanco-Alcaina, Elena
  • Suarez-Martinez, Elisa
  • Verdugo-Sivianes, Eva M.
  • Espinosa-Sánchez, Asunción
  • Sánchez-Díaz, Laura
  • Domínguez-Medina, Eduardo
  • Fernández-Rozadilla, Ceres
  • Carracedo, Ángel
  • Wu, Lindsay E.
  • Carnero, Amancio
© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data., Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous group of tumors that affect different anatomical locations. Despite this heterogeneity, HNSCC treatment depends on the anatomical location, TNM stage and resectability of the tumor. Classical chemotherapy is based on platinum-derived drugs (cisplatin, carboplatin and oxaliplatin), taxanes (docetaxel, paclitaxel) and 5-fluorouracil1. Despite advances in HNSCC treatment, the rate of tumor recurrence and patient mortality remain high. Therefore, the search for new prognostic identifiers and treatments targeting therapy-resistant tumor cells is vital. Our work demonstrates that there are different subgroups with high phenotypic plasticity within the CSC population in HNSCC. CD10, CD184, and CD166 may identify some of these CSC subpopulations with NAMPT as a common metabolic gene for the resilient cells of these subpopulations. We observed that NAMPT reduction causes a decrease in tumorigenic and stemness properties, migration capacity and CSC phenotype through NAD pool depletion. However, NAMPT-inhibited cells can acquire resistance by activating the NAPRT enzyme of the Preiss-Handler pathway. We observed that coadministration of the NAMPT inhibitor with the NAPRT inhibitor cooperated inhibiting tumor growth. The use of an NAPRT inhibitor as an adjuvant improved NAMPT inhibitor efficacy and reduced the dose and toxicity of these inhibitors. Therefore, it seems that the reduction in the NAD pool could have efficacy in tumor therapy. This was confirmed by in vitro assays supplying the cells with products of inhibited enzymes (NA, NMN or NAD) and restoring their tumorigenic and stemness properties. In conclusion, the coinhibition of NAMPT and NAPRT improved the efficacy of antitumor treatment, indicating that the reduction in the NAD pool is important to prevent tumor growth., This research was funded by Grants RTI2018-097455-B-I00 and PID2021-122629OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, by the “European Union”. Additional grants from CIBER de Cáncer (CB16/12/00275), from Consejeria de Salud (PI-0397–2017) and Project P18-RT-2501 from 2018 competitive research projects call within the scope of PAIDI 2020—80% co-financed by the European Regional Development Fund (ERDF) from the Regional Ministry of Economic Transformation, Industry, Knowledge and Universities. Junta de Andalucía. Special thanks to the AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR for supporting this work. AES was funded by a grant from the Fundación AECC. EMVS was funded by a postdoctoral fellowship from Junta de Andalucía (CTEICU/PAIDI 2020). LEN, ES-M and LS-D were funded by Spanish ministry of education (FPU16/0290; FPU17/02173; FPU18/01009)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Multitasker Protein: A Look at the Multiple Capabilities of NUMB

  • Ortega-Campos, Sara M.
  • García-Heredia, José Manuel
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., NUMB, a plasma membrane-associated protein originally described in Drosophila, is involved in determining cell function and fate during early stages of development. It is secreted asymmetrically in dividing cells, with one daughter cell inheriting NUMB and the other inheriting its antagonist, NOTCH. NUMB has been proposed as a polarizing agent and has multiple functions, including endocytosis and serving as an adaptor in various cellular pathways such as NOTCH, Hedgehog, and the P53-MDM2 axis. Due to its role in maintaining cellular homeostasis, it has been suggested that NUMB may be involved in various human pathologies such as cancer and Alzheimer’s disease. Further research on NUMB could aid in understanding disease mechanisms and advancing the field of personalized medicine and the development of new therapies., This work was supported by different grants: Grants RTI2018-097455-B-I00 and PID2021-122629OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, by the “European Union”. Additional grants from CIBER de Cáncer (CB16/12/00275), from Consejeria de Salud (PI-0397-2017) and Project P18-RT-2501 from 2018 competitive research projects call within the scope of PAIDI 2020—80% co-financed by the European Regional Development Fund (ERDF) from the Regional Ministry of Economic Transformation, Industry, Knowledge and Universities. Junta de Andalucía. Special thanks to the AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR for supporting this work., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Interactions of circadian clock genes with the hallmarks of cancer

  • Ortega-Campos, Sara M.
  • Verdugo-Sivianes, Eva M.
  • Amiama-Roig, Ana
  • Blanco, José Ramón
  • Carnero, Amancio
The molecular machinery of the circadian clock regulates the expression of many genes and processes in the organism, allowing the adaptation of cellular activities to the daily light-dark cycles. Disruption of the circadian rhythm can lead to various pathologies, including cancer. Thus, disturbance of the normal circadian clock at both genetic and environmental levels has been described as an independent risk factor for cancer. In addition, researchers have proposed that circadian genes may have a tissue-dependent and/or context-dependent role in tumorigenesis and may function both as tumor suppressors and oncogenes. Finally, circadian clock core genes may trigger or at least be involved in different hallmarks of cancer. Hence, expanding the knowledge of the molecular basis of the circadian clock would be helpful to identify new prognostic markers of tumorigenesis and potential therapeutic targets., This work was supported by Grants RTI2018–097455-B-I00 and PID2021-122629OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, by the “European Union”. Additional grants from CIBER de Cáncer (CB16/12/00275), from Consejeria de Salud (PI-0397-2017) and Project P18-RT-2501 from 2018 competitive research projects call within the scope of PAIDI 2020—80% co-financed by the European Regional Development Fund (ERDF) from the Regional Ministry of Economic Transformation, Industry, Knowledge and Universities. Junta de Andalucía. Special thanks to the AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR for supporting this work. EMV-S was funded by a postdoctoral contract from Consejeria of Transformacion Economica, Industria, Conocimiento, y Universidades of the Junta de Andalucia, Spain (No. CTEICU/PAIDI 2020, DOC_01655)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Essential role of PLD2 in hypoxia-induced stemness and therapy resistance in ovarian tumors

  • Muñoz-Galván, Sandra
  • Verdugo-Sivianes, Eva M.
  • Santos-Pereira, José M.
  • Estévez-García, Purificación
  • Carnero, Amancio
[Background] Hypoxia in solid tumors is an important source of chemoresistance that can determine poor patient prognosis. Such chemoresistance relies on the presence of cancer stem cells (CSCs), and hypoxia promotes their generation through transcriptional activation by HIF transcription factors., [Methods] We used ovarian cancer (OC) cell lines, xenograft models, OC patient samples, transcriptional databases, induced pluripotent stem cells (iPSCs) and Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq)., [Results] Here, we show that hypoxia induces CSC formation and chemoresistance in ovarian cancer through transcriptional activation of the PLD2 gene. Mechanistically, HIF-1α activates PLD2 transcription through hypoxia response elements, and both hypoxia and PLD2 overexpression lead to increased accessibility around stemness genes, detected by ATAC-seq, at sites bound by AP-1 transcription factors. This in turn provokes a rewiring of stemness genes, including the overexpression of SOX2, SOX9 or NOTCH1. PLD2 overexpression also leads to decreased patient survival, enhanced tumor growth and CSC formation, and increased iPSCs reprograming, confirming its role in dedifferentiation to a stem-like phenotype. Importantly, hypoxia-induced stemness is dependent on PLD2 expression, demonstrating that PLD2 is a major determinant of de-differentiation of ovarian cancer cells to stem-like cells in hypoxic conditions. Finally, we demonstrate that high PLD2 expression increases chemoresistance to cisplatin and carboplatin treatments, both in vitro and in vivo, while its pharmacological inhibition restores sensitivity., [Conclusions] Altogether, our work highlights the importance of the HIF-1α-PLD2 axis for CSC generation and chemoresistance in OC and proposes an alternative treatment for patients with high PLD2 expression., This research was funded by Grants RTI2018-097455-B-I00 and PID2021-122629OB-I00 funded by MCIN/AEI and by “ERDF A way of making Europe”, by the “European Union”. Additional grants from CIBER de Cáncer (CB16/12/00275), from Consejeria de Salud (PI-0397-2017) and Project P18-RT-2501 from 2018 competitive research projects call within the scope of PAIDI 2020—80% co-financed by the European Regional Development Fund (ERDF) from the Regional Ministry of Economic Transformation, Industry, Knowledge and Universities. Junta de Andalucía. Special thanks to the AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR for supporting this work. SMG was funded by a grant from the Fundación AECC. EMV-S is funded by postdoctoral fellowships from Junta de Andalucía (DOC_01655). JMS-P is funded by an Emergia grant from Junta de Andalucía (EMC21_00188). Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Hypoxia-induced immortalization of primary cells depends on Tfcp2L1 expression

  • Otero-Albiol, Daniel
  • Santos-Pereira, José M.
  • Lucena-Cacace, Antonio
  • Clemente-González, Cynthia
  • Muñoz-Galván, Sandra
  • Yoshida, Yoshinori
  • Carnero, Amancio
Cellular senescence is a stress response mechanism that induces proliferative arrest. Hypoxia can bypass senescence and extend the lifespan of primary cells, mainly by decreasing oxidative damage. However, how hypoxia promotes these effects prior to malignant transformation is unknown. Here we observed that the lifespan of mouse embryonic fibroblasts (MEFs) is increased when they are cultured in hypoxia by reducing the expression of p16INK4a, p15INK4b and p21Cip1. We found that proliferating MEFs in hypoxia overexpress Tfcp2l1, which is a main regulator of pluripotency and self-renewal in embryonic stem cells, as well as stemness genes including Oct3/4, Sox2 and Nanog. Tfcp2l1 expression is lost during culture in normoxia, and its expression in hypoxia is regulated by Hif1α. Consistently, its overexpression in hypoxic levels increases the lifespan of MEFs and promotes the overexpression of stemness genes. ATAC-seq and Chip-seq experiments showed that Tfcp2l1 regulates genes that control proliferation and stemness such as Sox2, Sox9, Jarid2 and Ezh2. Additionally, Tfcp2l1 can replicate the hypoxic effect of increasing cellular reprogramming. Altogether, our data suggest that the activation of Tfcp2l1 by hypoxia contributes to immortalization prior to malignant transformation, facilitating tumorigenesis and dedifferentiation by regulating Sox2, Sox9, and Jarid2., This work is supported by Grants RTI2018-097455-B-I00 and PID2021-122629OB-I00 funded by MCIN/ AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, by the “European Union”. Additional grants from CIBER de Cáncer (CB16/12/00275), from Consejeria de Salud (PI-0397-2017) and Project P18-RT-2501 from 2018 competitive research projects call within the scope of PAIDI 2020—80% co-financed by the European Regional Development Fund (ERDF) from the Regional Ministry of Economic Transformation, Industry, Knowledge and Universities. Junta de Andalucía. Special thanks to the AECC (Spanish Association of Against Cancer) Founding Ref. GC16173720CARR for supporting this work.special thanks to the Fundacion AECC and Fundacion BBVA for supporting this work. YY was funded by a grant from Japan Agency for Medical Research and Derevelopment (JP20bm0804022) and a grant from the Leducq Foundation (18CVD05). JMS-P was funded by a postdoctoral fellowship from Junta de Andalucía (DOC_00512)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Protein homeostasis maintained by HOOK1 levels promotes the tumorigenic and stemness properties of ovarian cancer cells through reticulum stress and autophagy

  • Suarez-Martinez, Elisa
  • Piersma, Sander R.
  • Pham, Thang V.
  • Bijnsdorp, Irene V.
  • Jimenez, Connie R.
  • Carnero, Amancio
Ovarian cancer has a high mortality rate mainly due to its resistance to currently used therapies. This resistance has been associated with the presence of cancer stem cells (CSCs), interactions with the microenvironment, and intratumoral heterogeneity. Therefore, the search for new therapeutic targets, particularly those targeting CSCs, is important for improving patient prognosis. HOOK1 has been found to be transcriptionally altered in a substantial percentage of ovarian tumors, but its role in tumor initiation and development is still not fully understood., This research was supported by grants from Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I + D + I 2018, Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): RTI2018-097455-B-I00 and PID2021-122629OB-I00 funded by MCIN/AEI/https://doi.org/10.13039/501100011033 and by “ERDF A way of making Europe”, by the “European Union”; AEI-MICIU/FEDER (iDIFFER network RED2022-134792-T). Additional grants from CIBER de Cáncer (CB16/12/00275), from Consejeria de Salud (PI-0397-2017) and Project P18-RT-2501 from 2018 competitive research projects call within the scope of PAIDI 2020—80% co-financed by the European Regional Development Fund (ERDF) from the Regional Ministry of Economic Transformation, Industry, Knowledge and Universities. Junta de Andalucía. Special thanks to the AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR for supporting this work. Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

MEG8 as an antagonistic pleiotropic mechanism in breast cancer

  • Verdugo-Sivianes, Eva M.
  • Espinosa-Sánchez, Asunción
  • Cases, Ildefonso
  • Rojas Mendoza, Ana M.
  • Otero-Albiol, Daniel
  • Romero, Lourdes
  • Blanco, José Ramón
  • Carnero, Amancio
Cellular senescence connects aging and cancer. Cellular senescence is a common program activated by cells in response to various types of stress. During this process, cells lose their proliferative capacity and undergo distinct morphological and metabolic changes. Senescence itself constitutes a tumor suppression mechanism and plays a significant role in organismal aging by promoting chronic inflammation. Additionally, age is one of the major risk factors for developing breast cancer. Therefore, while senescence can suppress tumor development early in life, it can also lead to an aging process that drives the development of age-related pathologies, suggesting an antagonistic pleiotropic effect. In this work, we identified Rian/MEG8 as a potential biomarker connecting aging and breast cancer for the first time. We found that Rian/MEG8 expression decreases with age; however, it is high in mice that age prematurely. We also observed decreased MEG8 expression in breast tumors compared to normal tissue. Furthermore, MEG8 overexpression reduced the proliferative and stemness properties of breast cancer cells both in vitro and in vivo by activating apoptosis. MEG8 could exemplify the antagonistic pleiotropic theory, where senescence is beneficial early in life as a tumor suppression mechanism due to increased MEG8, resulting in fewer breast tumors at an early age. Conversely, this effect could be detrimental later in life due to aging and cancer, when MEG8 is reduced and loses its tumor-suppressive role., This work was supported by grants from the Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I + D + I 2018, Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): RTI2018-097455-B-I00, and PID2021-122629OB-I00 grant from AEI-MICIU/FEDER (RED2022-134792-T iDIFFER network); from CIBER de Cáncer (CB16/12/00275), co-funded by FEDER from Regional Development European Funds (European Union); from Consejería de Salud (PI-0397-2017) and from Consejería de Economía, Conocimiento, Empresas y Universidad de la Junta de Andalucía (P18-RT-2501). Special thanks to the AECC Foundation (Spanish Association of Cancer Research) for supporting this work (founding ref. GC16173720CARR). EMV-S was funded by a postdoctoral contract from Consejería de Transformación Económica, Industria, Conocimiento, y Universidades de la Junta de Andalucía, Spain (CTEICU/PAIDI 2020, DOC_01655)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

PSMG2 role in tumorigenesis and stemness mediated by protein accumulation, reticulum stress and autophagy

  • Espinosa-Sánchez, Asunción
  • Blanco-Alcaina, Elena
  • Carnero, Amancio
The analysis of the dedifferentiation process has suggested that differentiated tumor cells undergo transformation toward cancer stem cells, accompanied by an increase in resistance to current chemotherapeutic treatments. Head and neck cancer (HNSCC) is a tumor with a high incidence and bad prognosis, and it is necessary to identify genes with alterations that can be explored therapeutically. PSMG2 is a chaperone protein that forms a heterodimer with PSMG1 and promotes the assembly of the 20S proteasome. Here, we characterized the effect of PSMG2 downregulation on tumorigenesis and the dedifferentiation process in head and neck cancer cell lines. We observed that high PSMG2 levels are associated with poor prognosis and survival in patients with HNSCC. Knockdown of PSMG2 reduced proliferation in vitro and in vivo in HNSCC cell lines. Moreover, the downregulation of PSMG2 diminished stemness, dedifferentiation and reprogramming properties. The reduction in PSMG2 levels caused the accumulation of polyubiquitinated proteins, increasing endoplasmic reticulum (ER) stress and activating apoptosis and autophagy as compensatory mechanisms. Furthermore, the response to proteasome inhibitors was increased in low-level PSMG2 patients. Therefore, PSMG2 is implicated in the assembly of the proteasome, which regulates ER stress as an essential cellular mechanism and autophagy and apoptosis as compensatory mechanisms for cellular homeostasis. PSMG2, and by extension the proteasome, is involved in cellular reprogramming and stemness., This research was supported by grants from Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I+D+I 2018, Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): RTI2018-097455-B-I00 and PID2021-122629OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by "ERDF A way of making Europe", by the "European Union"; AEI-MICIU/FEDER (iDIFFER network RED2022-134792-T). Additional grants from CIBER de Cáncer (CB16/12/00275), from Consejeria de Salud (PI-0397-2017) and Project P18-RT-2501 and DGP_PIDI_2024_00907, from the Regional Ministry of Economic Transformation, Industry, Knowledge and Universities (Junta de Andalucía), co-financed by the European Regional Development Fund (ERDF). Special thanks to the AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR for supporting this work. Special thanks to the AECC Foundation for supporting this work. AES was funded by a predoctoral grant from the AECC Foundation (PRDSE19002ESPI)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Efficacy of NAMPT Inhibitors in Pancreatic Cancer After Stratification by MAP17 (PDZK1IP1) Levels

  • Verdugo-Sivianes, Eva M.
  • Martínez-Pérez, Julia
  • Navas, Lola E.
  • Sáez, Carmen
  • Carnero, Amancio
This article belongs to the Section Molecular Cancer Biology., [Data Availability Statement] Data from publicly available clinical and genomic information were obtained from the R2 Genomics analysis and visualization platform (https://hgserver1.amc.nl/cgi-bin/r2/main.cgi; accessed on January 2025), the TCGA Research Network (https://cancergenome.nih.gov/; accessed on November 2022) and the TISCH resource (http://tisch1.comp-genomics.org/; accessed on November 2022) [25]., [Simple Summary] Pancreatic cancer (PC) is the seventh leading cause of cancer-related deaths globally, marked by a high mortality due to its aggressive nature and late diagnosis. Although surgical resection is the only curative option, most cases are diagnosed too late for surgery. This study identifies potential treatment vulnerabilities by focusing on MAP17 (PDZK1IP1), whose high mRNA expression correlates with poor prognosis and is found exclusively in tumor cells. In 2D cultures, MAP17-expressing cells responded better to gemcitabine and 5-fluorouracil. However, in vivo xenograft models showed resistance to all treatments. These cells also had elevated NAD levels, which could be depleted using NAMPT inhibitors. Indeed, depletion of NAD seems to resensitize MAP17-expressing tumors to chemotherapy. Thus, MAP17 may serve as a prognostic marker and therapeutic target. Combining NAMPT inhibitors with standard therapies could enhance treatment efficacy in patients with high MAP17 expression., [Background/Objectives:] Pancreatic cancer (PC) is the seventh leading cause of cancer-related deaths worldwide, with its incidence rising each year. Despite its relatively low incidence, the aggressiveness of pancreatic cancer results in high mortality, with only 12% of patients surviving five years post-diagnosis. Surgical resection remains the only potentially curative treatment, but the tumor is often diagnosed at an advanced stage. The goal of this work is to identify vulnerabilities that can affect the efficacy of treatments and improve the efficacy of therapy., [Methods:] MAP17 overexpression in pancreatic cancer cell lines, RT-qPCR analysis, xenografts, in vitro and in vivo treatments, analysis of data from pancreatic tumors in transcriptomic patient databases., [Results:] We studied the prognostic and predictive value of MAP17 (PDZK1IP1) expression in pancreatic cancer, and we found that high MAP17 mRNA expression was associated with poor prognosis. In addition, single-cell analysis revealed that high MAP17 expression was present only in tumor cells. We investigated whether the response to various antitumor agents depended on MAP17 expression. In 2D culture, MAP17-expressing pancreatic cancer cells responded better to gemcitabine and 5-fluorouracil. However, in vivo xenograft tumors with MAP17 expression showed resistance to all treatments. Additionally, MAP17-expressing cells had a high NAD pool, which seems to be effectively depleted in vivo by NAMPT inhibitors, the primary enzyme for NAD biosynthesis., [Conclusions:] Our findings suggest that MAP17 expression could enhance the prognostic stratification of pancreatic cancer patients. Moreover, the coadministration of NAMPT inhibitors with current treatments may sensitize tumors with high MAP17 expression to chemotherapy and improve the efficacy of chemotherapy., This work was supported by grants from the Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I+D+I 2018, Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): RTI2018-097455-B-I00, and a PID2021-122629OB-I00 grant from AEI-MICIU/FEDER (RED2018-102723-T); from CIBER de Cáncer (CB16/12/00275), co-funded by FEDER from Regional Development European Funds (European Union); from Consejería de Salud (PI-0397-2017) and from Consejería de Economía, Conocimiento, Empresas y Universidad de la Junta de Andalucía (P18-RT-2501). Special thanks to the AECC Foundation (Spanish Association of Cancer Research) for supporting this work (founding ref. GC16173720CARR). EMV-S was funded by a postdoctoral contract from Consejería de Transformación Económica, Industria, Conocimiento, y Universidades de la Junta de Andalucía, Spain (CTEICU/PAIDI 2020, DOC_01655). JM-P was funded by a Rio Hortega contract from Instituto de Salud Carlos III (ISCIII, CM18/00219). We also thanks the COST action TRANSPAN (Action CA21116). The funders played no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tfcp2l1 as a central integrator of hypoxia, dedifferentiation, and tumor progression

  • Clemente-González, Cynthia
  • Carnero, Amancio
The gene Tfcp2l1 has emerged as a central player linking key processes in cancer biology: hypoxia, immortalization, dedifferentiation, and tumor progression. Originally identified for its role in maintaining pluripotency in embryonic stem cells, Tfcp2l1 has been found to reappear in various cancers, especially under conditions of low oxygen (hypoxia). Hypoxia, a common feature of solid tumors, triggers the reactivation of developmental genes like Tfcp2l1, enabling cancer cells to dedifferentiate and adopt stem cell-like properties. This dedifferentiation facilitates the immortalization of cells—allowing them to bypass senescence and continue proliferating. Tfcp2l1 contributes to this process by regulating transcriptional networks that suppress differentiation and support self-renewal. Its expression correlates with poor prognosis in several cancers, highlighting its potential role in tumor aggressiveness and resistance to therapy. By acting at the intersection of cellular plasticity, stress adaptation, and oncogenic transformation, Tfcp2l1 may serve as a molecular bridge linking early developmental programs with malignant behaviors. Understanding how Tfcp2l1 integrates signals from hypoxic stress and drives dedifferentiation could uncover new therapeutic targets aimed at reversing or halting tumor progression., This work was supported by grants from the Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I+D+I, Agencia Estatal deInvestigación (AEI) and Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER,UE): PID2021-122629OB-I00, PID2024-155394OB-I00 and RED2024-153635-T (iDIFFER network) grants from AEI-MICIU/ 10.13039/501100011033 and, by “ERDF A way of making Europe”, by the “European Union” or by the “European Union Next Generation EU/PRTR” from CIBER de Cáncer(CB16/12/00275), co-funded by FEDER from Regional Development European Funds (European Union); from Consejería de Salud and from Consejería de Economía, Conocimiento, Empresas y Universidad de la Junta de Andalucía (DGP_PIDI_2024_00907). Special thanks to the AECC Foundation (Spanish Association of Cancer Research) for supporting this work (founding ref. GC16173720CARR)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Integrative multi-omic analysis reveals a PAX8-driven gene network linking tumor stemness to therapy response in ovarian cancer

  • Santos-Pereira, José M.
  • Carnero, Amancio
  • Muñoz-Galván, Sandra
[Data availability] The public datasets in cell lines used in this study are available in the following databases: Gene Expression Omnibus with accession codes GSE227779 [55], GSE114964 [89], and GSE195677 [52]; Sequence Read Archive with accession codes PRJNA655844 [23] and PRJNA749469 [54]; and DNA Data Bank of Japan with accession code DRA010685 [53]. The patient datasets used in this study are available in the Gene Expression Omnibus with accession codes GSE18520, GSE204748, GSE38666, GSE40595, GSE63885, and GSE73168 [51–59, 63] and in the TCGA Research Network: https://www.cancer.gov/tcga., The transcription factor PAX8 is expressed in most ovarian tumors, being associated with increased tumorigenesis. Although recent studies have addressed the gene regulatory functions of PAX8 in ovarian cancer, an integrative analysis of multi-omic and patient data is required to identify the core regulatory network of PAX8 and its prognostic and therapeutic value. Here, we integrate PAX8 chromatin binding and accessibility data in ovarian cancer cells with transcriptomic and patients' data to gain insight into the core gene regulatory network orchestrated by PAX8 in ovarian tumors. Integration of differential chromatin accessibility, transcription factor binding, and gene expression upon PAX8 knockout provides a core regulatory network that explains most of the genes regulated by PAX8. We combine these target genes with patient expression data and find a PAX8 gene signature associated with tumor stemness, a property related to therapy resistance. Indeed, we show that the PAX8 gene signature predicts disease outcome and response to therapy in ovarian cancer patients. Finally, we validated experimentally our results from bioinformatic analyses, thus reassuring their robustness. Our findings uncover a PAX8 core network that represents a promising strategy for targeted antitumor therapies and open new pathways to fight against ovarian cancer resistance., SM-G is funded by grants from Fundación Ramón Areces (Proyecto Vida y Materia 2024); and grant PI-0121-2024 from Consejería de Salud y Consumo, Junta de Andalucía. AC is funded by grant PID2021-122629OB-I00 by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe” by the “European Union”; and by CIBER de Cáncer (CB16/12/00275). JMS-P is funded by “Emergia” Grant EMC21_00188 by Junta de Andalucía; grant PID2023-147172NA-I00 by MICIU/AEI/ 10.13039/501100011033 and by the “European Union”; and grant CNS2023-143945 by MICIU/AEI/10.13039/501100011033 and by “European Union NextGenerationEU/PRTR.”, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Interleukin-11 promotes lung adenocarcinoma tumourigenesis and immune evasion

  • Cirauqui, Cristina
  • Ojeda, Laura
  • Otano, Itziar
  • Pazos, Irene
  • Santos, Alba
  • Garrido-Martin, Eva M.
  • Yagüe, Patricia
  • Ramos-Paradas, Javier
  • Molina-Pinelo, Sonia
  • Roncador, Giovanna
  • Solórzano, José Luis
  • Muñoz Jiménez, María Teresa
  • Cozar, Patricia
  • Plaza, Patricia
  • Suárez, Rocío
  • Jiménez, Marta
  • Moreno, Roberto
  • Rosado, Arantxa
  • Gámez, Pablo
  • García-Luján, Ricardo
  • Zugazagoitia, Jon
  • Sweet-Cordero, Alejandro
  • Barbacid, Mariano
  • Carnero, Amancio
  • Ferrer, Irene
  • Paz-Ares, Luis
Cristina Cirauqui, Laura Ojeda, Irene Ferrer and Luis Paz-Ares contributed equally to this work., [Rationale] Interleukin-11 (IL-11) has emerged as a significant player in tumourigenesis, with implications across various cancer types. However, its specific role in driving tumour progression in lung adenocarcinoma (LUAD) remains elusive. IL-11's multifaceted impact on both tumour cells and the tumour microenvironment underscores its potential as a therapeutic target in LUAD. This study aims to unravel the involvement of IL-11 in LUAD progression and its influence on the tumour microenvironment., [Methods] Here, we used transcriptomic and digital spatial profiling analyses together with clinic data from two retrospective LUAD patient cohorts. LUAD cell lines genetically engineered to overexpress or to silence IL-11 or its receptor (IL-11RA) were used for in vitro functional analysis and for in vivo experiments. Additionally, we used three different in vivo models: patient-derived xenografts (PDXs), tobacco-exposed mice and genetically engineered mouse models. A neutralising monoclonal antibody against IL-11RA was produced and tested., [Results] Our findings revealed a pivotal role for IL-11 in driving tumourigenesis across various mouse models, highlighting its capacity to modulate tumour immunity towards an immunosuppressive microenvironment. Moreover, we observed a correlation between IL-11 expression and poorer patient outcomes in LUAD. Notably, therapeutic targeting of IL-11RA with a neutralising antibody demonstrated significant anti-tumour efficacy in a PDX model., [Conclusion] The IL-11/IL-11RA axis emerges as a critical driver of LUAD tumourigenesis, exerting its effects through enhanced tumour cell proliferation and remodelling of the tumour microenvironment. Our study highlights the therapeutic potential of disrupting this axis, suggesting that patients exhibiting elevated IL-11 levels may benefit from therapies targeting the IL-11/IL-11RA pathway., We would like to acknowledge patients and their families for donating tumour tissue. We would also like to thank Alicia Maroto Pérez and Carolina Castilla, as well as the Biobank of the Hospital 12 de Octubre and Hospital Virgen del Rocío for kindly providing the samples used in this study. Appreciation is also expressed to Ines Muñoz and Jorge L. Martinez-Torrecuadrada (CNIO) for producing the recombinant human IL-11 and IL-11RA. L.P.-A. was funded by CAM, (B2017/BMD3884, P2022/BMD-7437), Fundación CRIS contra el cancer, CIBERONC (CD16/12/00442) and ISCIII (PI17/00778; PI20/00870; AC20/0070) and I.F. by AECC (AIO2015) and ISCIII (PI16/01311; PI19/00320; CP21/00052) and co-funded by FEDER (European Union). L.O. is funded by the Spanish Ministry of Education (FPU13/02595) and C.C. by ISCIII (CD21/00165). AC was funded by grants from the Ministerio de Ciencia, Innovación y Universidades (MCIU), Plan Estatal de I+D+I 2021, Agencia Estatal de Investigación (AEI), Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): ID2021-122629OB-I00 and CIBER de Cáncer (CB16/12/00275). EASC was funded by U01CA199216 from the National Cancer Institute. S.M.-P. was funded by the Ministry of Health and Social Welfare of the Junta de Andalucía (Nicolas Monardes Program RC-0004-2020, and PECART-0091-2020), Andalusian Research, Development and Innovation Plan (PY20_00992) and ISCIII (PI20/01109) and co-funded by FEDER from Regional Development European Funds (European Union)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

HOOK2 downregulation compromises the tumorigenic and stemness properties of ovarian cancer cells by increasing endoplasmic reticulum stress

  • Suarez-Martinez, Elisa
  • Espinosa-Sánchez, Asunción
  • Piersma, Sander R.
  • Pham, Thang V.
  • Bijnsdorp, Irene V.
  • Jimenez, Connie R.
  • Carnero, Amancio
[Data availability] All data and materials will be available upon reasonable request. Raw proteomics data can be downloaded from the ProteomXchange repository (dataset identifier PXD050782)., Ovarian cancer stands out as one of the tumors with a high mortality rate in women. Therefore, the search for new therapeutic targets is essential to enhance patient prognosis. There is evidence suggesting that HOOK2, an adaptor protein involved in microtubule transport, may play a role in cancer, particularly ovarian cancer. This study examines the role of HOOK2 in the progression of ovarian tumors. The findings reveal that a decrease in HOOK2 levels leads to diminished growth and cellular migration in ovarian cancer cells, impeding the in vivo formation of tumors. The reduction of HOOK2 is associated with both an increase in endoplasmic reticulum stress and an elevation in cell death, the latter likely caused by the activation of the unfolded protein response. Moreover, the study observes that the decrease in HOOK2 diminishes the properties of cancer stem cells in ovarian cancer, possibly due to the increase in cell death specifically found within these stem cells. Given the profound impact of reduced HOOK2 levels on ovarian cancer cells, this gene emerges as a promising therapeutic strategy for treating ovarian cancer patients., This research was supported by grants from Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I + D + I 2018, Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): PID2024-155394OB-I00 and PID2021-122629OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, by the “European Union”; AEI-MICIU/FEDER (RED2024-153635-T (iDIFFER network)). Additional grants from CIBER de Cáncer (CB16/12/00275), from Consejería de Economía, Conocimiento, Empresas y Universidad de la Junta de Andalucía (DGP_PIDI_2024_00907), co-financed by the European Regional Development Fund (ERDF) (Junta de Andalucía). AE-S was hired under the Generation D initiative, promoted by Red.es, an organization attached to the Ministry for Digital Transformation and the Civil Service, for the attraction and retention of talent through grants and training contracts, financed by the Recovery, Transformation and Resilience Plan through the European Union’s Next Generation funds. Special thanks to the AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR for supporting this work., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Role of WDR66 in Stemness, Therapy Resistance and Tumor microenvironment modulation in Head and Neck Cancer

  • Sánchez-Díaz, Laura
  • Espinosa-Sánchez, Asunción
  • Carnero, Amancio
Head and neck cancer comprises a variety of malignant tumors affecting regions such as the oral cavity, pharynx, larynx, paranasal sinuses, nasal cavity and salivary glands. These tumors are highly heterogeneous, making it difficult to identify specific biomarkers and effective treatments, increasing mortality and recurrence rates. Databases analyzed to identify genes with altered expression in tumor tissue showed WDR66 able predict prognosis and survival, in HNSCC, but whose involvement in tumorigenesis is unknown. High WDR66 expression was associated with a worse prognosis, although its overexpression did not significantly alter basic tumor properties in cancer cells in vitro or in vivo. However, we observed an increase in pluripotency factors (OCT3/4, SOX2, KLF4, LIN28), resistance to chemotherapies and a decrease in apoptosis. Consistently, decreasing WDR66 expression using CRISPR showed a reduction in tumorsphere formation, lower expression of pluripotency-related genes, decreased cell migration, and increased sensitivity to cisplatin. These effects were more pronounced in vivo, suggesting a relevant role of WDR66 in the tumor microenvironment. The medium conditioned by cells overexpressing WDR66 promoted migration, maintained the stem cell phenotype, and inhibited immune differentiation, harboring soluble factors involved in progression and metastasis. In this media, we identified several cytokines and growth factors related to inflammation and immune system modulation. In conclusion, WDR66 emerges as a potential biomarker of poor prognosis and a possible predictor of response to immunotherapy, given its impact on cellular pluripotency, treatment resistance and modification of the tumor microenvironment in head and neck cancer., This research was supported by grants from Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I+D+I 2018, Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): PID2021-122629OB-I00 and PID2024-155394OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, by the “European Union”; AEI-MICIU/FEDER (iDIFFER network RED2024-153635-T). Additional grants from CIBER de Cáncer (CB16/12/00275), from competitive research projects call within the scope of PAIDI 2020—80% co-financed by the European Regional Development Fund (ERDF) from the Regional Ministry of Economic Transformation, Industry, Knowledge and Universities. Junta de Andalucía (DGP_PIDI_2024_00907). Special thanks to the AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR. AE-S staff hired under the Generation D initiative, promoted by Red.es, an organization attached to the Ministry for Digital Transformation and the Civil Service, for the attraction and retention of talent through grants and training contracts, financed by the Recovery, Transformation and Resilience Plan through the European Union's Next Generation funds., Peer reviewed, Modelo experimental animal
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tumoral switch in NUMB splicing changes essential transcription pathways and induces malignant properties in tumour cells

  • García-Heredia, J. M.
  • Ortega-Campos, Sara M.
  • Carnero, Amancio
[Data availability] Availability of data and materials All datasets analysed in this study are publicly available. Breast cancer datasets from the Gene Expression Omnibus (GEO, RRID:SCR_005012), including GSE69031, GSE21653, GSE1456, GSE20685, GSE25066, GSE42568, GSE162228, and GSE12093, were used in this study and are publicly available at GEO [78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93]. TCGA-BRCA RNA-seq isoform expression and clinical data were obtained from the NCI Genomic Data Commons (GDC; RNA-seq Level 3 RSEM isoform-normalized data dated 2015–08-06). CCLE expression data were obtained from the Cancer Cell Line Encyclopedia (CCLE; RNA-seq transcript TPM file dated 2018–09-29), and drug-response data were integrated with GDSC (release dated 2023–10-27) after harmonising cell-line identifiers. Breast PDX isoform quantifications and metadata were obtained from the PDMR resource. Key analysis outputs and sample-level annotations, including transcript-level differential expression, pathway enrichment results, metabolic expression matrices, drug-response statistics, and NUMB-score assignments, are provided in the Supplementary Information files (Additional file 3: Tables S2–S10). All custom scripts used for data processing and analysis are publicly available at GitHub (https://github.com/jmgheredia/NUMB-tumoral-switch) and are distributed under an OSI-compliant open-source license (MIT License) [111]. The source code has also been permanently archived in Zenodo with an assigned DOI (https://doi.org/10.5281/zenodo.18522980) [112]., [Background] Emerging evidence indicates that cancer is associated with widespread splicing alterations that generate tumour-specific isoforms. One example is NUMB, an evolutionarily conserved adaptor protein, which produces four isoforms (p72, p71, p66, and p65) through alternative splicing of exons 3 and 9. Although traditionally considered as a tumour suppressor, NUMB has also been reported as an oncogene. We propose that this dual role reflects isoform-specific expression., [Results] Using public databases, we identify a tumour-associated switch in NUMB isoform expression: p72 and p71 are upregulated in tumours, whereas p66 and p65 are more highly expressed in non-tumour tissues. These isoforms show distinct associations with key cellular processes. NUMBL, a NUMB homolog, displays expression patterns similar to p65. We further identify two transcriptional clusters: one characterised by high expression of p72 and p71, and the other by enhanced p66/p65/NUMBL expression. These clusters exhibit differential associations with Notch, WNT/β-catenin, Hedgehog, and Hippo signalling pathways, suggesting isoform-specific regulatory roles. In breast cancer cell lines, we develop a NUMB-score based on isoform expression, which classifies cell lines into biologically distinct groups. The p72/p71-enriched group shows distinct signatures, pathway activity, and drug sensitivity. Application of this score to TCGA-BRCA samples reveals a significant link between high NUMB-score and poor survival, as confirmed by Kaplan–Meier analysis., [Conclusions] We find that NUMB emerges as a potential oncogenic contributor and biomarker in the context of splicing-based precision oncology, highlighting Isoform-specific expression as a clinical determinant of tumour behaviour, pathway activity, and therapeutic response., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This research was supported by grants from Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I + D + I 2018, Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): PID2024-155394OB-I00 and PID2021-122629OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, by the “European Union”; AEI-MICIU/FEDER (iDIFFER network: RED2024-153635-T). Additional grants from CIBER de Cáncer (CB16/12/00275), from Consejeria de Salud (PI-0397–2017) and Projects P18-RT-2501; and DGP_PIDI_2024_00907 from the Regional Ministry of Economic Transformation, Industry, Knowledge and Universities. Junta de Andalucía. Special thanks to the AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR for supporting this work., Peer reviewed